Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all subtypes of JIA according to ILAR criteria~* ages 4 to 9 (before the scheduled booster, normally administered at age 9 in the Netherlands)~* 5 healthy adults (aged 18 to 65y)~Exclusion Criteria:~* use of Infliximab (Remicade, anti-Tumor Necrosis Factor (TNF) alpha therapy).~* primary immunodeficiency~* fever less than 48 hour prior to vaccination (vaccination will be postponed for 1 month)~* evidence of viral or bacterial infection less than 48hours prior to vaccination (vaccination will be postponed for 1 month)~* methylprednisolone pulse therapy less than 1 month prior to vaccination (vaccination will be postponed for 1 month)~* transfusion of blood or blood products (e.g. intravenous immunoglobulins (IVIG)) in the 3 months prior to vaccination (vaccination will be postponed for 3 months)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Measles, mumps, rubella booster vaccination within 3 months after randomisation
- 2 (Type: NO_INTERVENTION): Booster vaccination performed by regular health authorities at age 9; at least 1 year after randomisation

Based on this trial design, predict the completion outcome and termination type (if applicable).